FDA approves Vyjuvek, first redosable gene therapy for dystrophic epidermolysis bullosa

Krystal Biotech/Vyjuvek

FDA approved Vyjuvek, the first redosable gene therapy and first approved treatment for both recessive and dominant DEB. Topical therapy delivers COL7A1 gene to wounds; enables reapplication.